摘要
目的分析晚期非小细胞肺癌(NSCLC)患者化疗联合血管内皮抑素治疗前后外周血中血管内皮生长因子(VEGF)和碱性成纤维生长因子(bFGF)的变化,探讨两者在NSCLC中的应用价值。方法用酶联免疫吸附试验(ELlSA)检测32例晚期NSCLC患者化疗联合血管内皮抑素治疗前后临床疗效及VEGF和bFGF水平。结果晚期NSCLC患者经化疗联合血管内皮抑素治疗后临床受益率达80.6%。治疗前后血浆VEGF水平的差异无统计学意义(P>0.05),血浆bFGF水平在治疗前后的差异有统计学意义(P<0.05)。治疗前后血浆bFGF水平的变化与临床受益呈正相关,结果有统计学意义(P<0.01)。结论在化疗联合血管内皮抑素治疗晚期NSCLC中,bFGF是一个较好的预测疗效的指标。
Objective To explore the application value of chemotherapy combined with Endostatin in NSCLC after the analysis of chemotherapy combined with Endostatin in patients with advanced NSCLC before and after treatment in peripheral blood of VEGF and bFGF.Methods The clinical efficacy and plasma levels of VEGF and bFGF in 32 cases with advanced NSCLC were measured by ELISA before and after treatment of chemotherapy combined with Endostatin.Results The benefit rate was 80.6% in the combined treatment of advanced NSCLC.Between before and after treatment,there was a significant difference of bFGF（P0.05）.On the contrary,there was no significant difference of VEGF（P0.05）.The correlation between plasma level of bFGF and the benefit rate was found to be positive either before or after treatment,there was a significant difference（P0.01）.Conclusion The bFGF,as a biomarker,may be useful in predicting the efficacy of the combined treatment of advanced NSCLC.
出处
《实用临床医药杂志》
CAS
2011年第13期12-14,17,共4页
Journal of Clinical Medicine in Practice
